CALC

Business Context and Reporting Period

CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory processes, primarily targeting calcium release-activated calcium (CRAC) channels. The company's lead product candidate is Auxora (zegocractin), currently in Phase 2 trials for acute kidney injury (AKI) and acute pancreatitis. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss vs. Income: The company reported a net loss of $5.0 million in Q1 2025, compared to a net income of $0.1 million in Q1 2024. The prior year's income was driven by a $5.6 million gain from the change in fair value of warrant liabilities, whereas Q1 2025 saw a $1.7 million gain from fair value adjustments on warrants and a new promissory note.
• Operating Expenses: Total operating expenses increased 13% to $6.5 million. Research and development (R&D) expenses rose 43% to $4.2 million, primarily due to increased clinical trial activities and chemistry, manufacturing, and controls (CMC) costs for Auxora. General and administrative (G&A) expenses decreased 19% to $2.3 million, largely due to the absence of transaction costs associated with the 2024 Private Placement that were present in the prior year.
• Debt Financing: In February 2025, the company entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., receiving $10.0 million in gross proceeds (Tranche 1). This resulted in a new promissory note liability of $8.6 million (fair value) and interest expense of $0.4 million, compared to no debt interest expense in Q1 2024.
• Liquidity: Cash and short-term investments increased to $24.6 million from $18.3 million, bolstered by the new debt financing and $0.97 million in net proceeds from At-The-Market (ATM) offerings.

Guidance, Outlook, and Risks

• Cash Runway: Management believes current cash, cash equivalents, and short-term investments ($24.6 million) are sufficient to fund operations into the middle of 2026. However, these resources are insufficient to fund product candidates through regulatory approval or to pursue additional indications beyond the current KOURAGE trial without additional capital.
• Capital Needs: The company explicitly states it will need to obtain substantial additional funding to complete development and commercialization. Failure to raise capital could force delays or elimination of development programs.
• Debt Covenants: The new loan agreement includes customary affirmative and negative covenants and events of default. The loan bears interest at the greater of 5.00% plus the prime rate or 12.75% and is secured by a lien on all company assets, including intellectual property.
• ATM Capacity: Due to "Baby Shelf Limitations" related to public float, the company currently has no capacity for further ATM sales as of March 31, 2025.
• Key Risks: Significant risks include the uncertainty of clinical trial outcomes for Auxora, reliance on third-party manufacturers (including a single-source supplier in China for API), potential inability to raise additional capital, and the impact of fair value accounting on financial results due to warrant and debt liabilities.

Investor Verification Checklist

• Capital Adequacy: Verify the company's ability to secure additional funding before mid-2026, given the current lack of ATM capacity and the high cost of debt financing.
• Clinical Milestones: Monitor the progress and topline data of the KOURAGE Phase 2 trial in AKI, as Tranche 2 and Tranche 3 of the new loan ($22.5 million potential) are contingent on achieving specific clinical milestones.
• Debt Terms: Review the specific covenants and interest rate mechanics of the Avenue Venture Opportunities Fund loan, noting the high interest floor (12.75%) and the security interest in all assets.
• Supply Chain: Assess the risks associated with the single-source supplier in China for the active pharmaceutical ingredient (API) of Auxora, particularly regarding geopolitical trade restrictions.
• Non-GAAP Volatility: Understand that net income/loss is heavily influenced by non-cash fair value adjustments of warrants and debt, which may not reflect operational cash burn accurately.